Saltar al contenido
Saltar al contenido

Regulatory management option analysis

The regulatory management option analysis (RMOA) list includes substances for which an RMOA either is under development or has been completed since the start of the implementation of the SVHC Roadmap in February 2013.

For each substance, the table shows the assessing Member State (submitter), the concern, the outcome and the suggested follow-up from the RMOA, and the date of the latest update to the list entry.

Other process details and relevant documents are also available and can be accessed through the ‘Details’ icon for the list entry.

 

Disclaimer to the RMOA list

The responsibility for the content of an RMOA rests with the authority that developed it. It is possible that other authorities do not have the same view, and even develop a further RMOA. Any authority can consequently initiate a regulatory process but should indicate this by appropriate means, such as the Registry of Intentions.

RMOAs and their conclusions are compiled based on available information and may change in light of new information or further assessment.

Last updated 11 septiembre 2019. Database contains 222 unique substances/entries.
Filter the list
Latest update:
Date of intention:
Date of RMOA conclusion:

 
covering any of their individual isomers and combinations thereof
-
-
Netherlands
Other environmental toxicity
Other human toxicity
Concluded
Appropriate to initiate regulatory risk management action
SVHC
14/06/2019
Details
223-861-6
4098-71-9
Germany
Carcinogenic
Exposure
Mutagenic
Other human toxicity
Concluded
Appropriate to initiate regulatory risk management action
Restriction
23/09/2014
Details
210-658-2
620-92-8
Sweden
Endocrine disruption
Other human toxicity
Under development
Under development
No suggestion yet
01/10/2015
Details
200-539-3
62-53-3
Netherlands
Other environmental toxicity
Other human toxicity
Concluded
No need to initiate further regulatory risk management action at this time
None
05/07/2017
Details
212-039-2
753-73-1
Netherlands
Other human toxicity
Concluded
Appropriate to initiate regulatory risk management action
Other legislation
10/07/2015
Details
629-757-0
1224966-15-7
Netherlands
Other environmental toxicity
Other human toxicity
Concluded
No need to initiate further regulatory risk management action at this time
None
05/07/2017
Details
203-404-7
106-50-3
Netherlands
Other environmental toxicity
Other human toxicity
Concluded
Appropriate to initiate regulatory risk management action
CLH
Restriction
24/05/2019
Details
207-995-2
504-60-9
Netherlands
Other environmental toxicity
Other human toxicity
Concluded
Appropriate to initiate regulatory risk management action
Other legislation
15/08/2017
Details
215-181-3
1310-58-3
Sweden
Other human toxicity
Concluded
No need to initiate further regulatory risk management action at this time
Other
08/04/2015
Details
215-185-5
1310-73-2
Sweden
Other human toxicity
Concluded
No need to initiate further regulatory risk management action at this time
Other
08/04/2015
Details
A complex combination of hydrocarbons obtained from the distillation of crude oil or natural gasoline. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly in the range of C9 through C12 and boiling in the range of approximately 140°C to 220°C (284°F to 428°F).
265-191-7
64742-88-7
Denmark
Carcinogenic
Mutagenic
Other human toxicity
Pending
On hold
No suggestion yet
23/09/2014
Details
231-639-5
7664-93-9
Belgium
Carcinogenic
Exposure
Mutagenic
Under development
Under development
No suggestion yet
23/09/2014
Details
253-242-6
36861-47-9
Germany
Endocrine disruption
Concluded
Appropriate to initiate regulatory risk management action
SVHC
10/07/2015
Details
3-benzylidene camphor; 3-BC
239-139-9
15087-24-8
Germany
Endocrine disruption
Concluded
Appropriate to initiate regulatory risk management action
SVHC
10/07/2015
Details
-
5436-43-1
France
Endocrine disruption
Concluded
No need to initiate further regulatory risk management action at this time
Other
23/08/2019
Details
214-946-9
1222-05-5
France
Endocrine disruption
Under development
Under development
No suggestion yet
09/08/2019
Details
205-028-9
131-55-5
Denmark
Endocrine disruption
Under development
Under development
No suggestion yet
23/09/2014
Details
205-029-4
131-56-6
Denmark
Endocrine disruption
Under development
Under development
No suggestion yet
23/09/2014
Details
201-025-1
77-40-7
France
Endocrine disruption
Under development
Under development
No suggestion yet
07/03/2017
Details
216-036-7
1478-61-1
Sweden
Endocrine disruption
Concluded
Appropriate to initiate regulatory risk management action
CLH
20/12/2018
Details
DCHP
201-545-9
84-61-7
Sweden
Endocrine disruption
Concluded
Appropriate to initiate regulatory risk management action
SVHC
07/09/2015
Details
205-031-5
131-57-7
Denmark
Endocrine disruption
Under development
Under development
No suggestion yet
01/04/2015
Details
201-280-9
80-46-6
Germany
Endocrine disruption
Concluded
Appropriate to initiate regulatory risk management action
SVHC
07/03/2017
Details
231-512-4
7601-90-3
Germany
Endocrine disruption
Under development
Under development
No suggestion yet
13/06/2016
Details
203-585-2
108-46-3
Finland
Endocrine disruption
Concluded
Appropriate to initiate regulatory risk management action
CLH
05/09/2019
Details
202-830-0
100-21-0
France
Endocrine disruption
Concluded
No need to initiate further regulatory risk management action at this time
None
07/03/2017
Details
246-563-8
25013-16-5
France
Endocrine disruption
Concluded
Appropriate to initiate regulatory risk management action
Restriction
17/01/2019
Details
260-830-6
57583-54-7
France
Endocrine disruption
Concluded
Appropriate to initiate regulatory risk management action
Other
10/08/2018
Details
201-071-2
77-94-1
France
Endocrine disruption
Concluded
Appropriate to initiate regulatory risk management action
Other legislation
22/01/2019
Details
201-067-0
77-90-7
France
Endocrine disruption
Concluded
No need to initiate further regulatory risk management action at this time
None
07/11/2016
Details
202-924-1
101-20-2
France
Endocrine disruption
Concluded
Appropriate to initiate regulatory risk management action
Other
10/08/2018
Details
205-288-3
137-30-4
Denmark
Endocrine disruption
Under development
Under development
No suggestion yet
23/09/2014
Details
202-681-1
98-56-6
Netherlands
Carcinogenic
Under development
Under development
No suggestion yet
09/11/2017
Details
233-660-5
10294-40-3
Netherlands
Carcinogenic
Concluded
Appropriate to initiate regulatory risk management action
CLH
SVHC
08/07/2019
Details
215-133-1
1304-56-9
Netherlands
Carcinogenic
Under development
Under development
No suggestion yet
09/11/2017
Details
207-069-8
431-03-8
Netherlands
Carcinogenic
Under development
Under development
No suggestion yet
09/11/2017
Details

Export search results to:

Categories Display


Route: .live2